Live, attenuated Newcastle Disease Virus is a state-of-the-art platform for producing first-in-class mucosal vaccines.

We quickly and efficiently engineer NDV to express stabilized antigenic proteins, allowing us to create mucosal vaccines for a wide range of endemic and emerging viruses.

Our proven technology will bring safe and immunogenic vaccines for all humans, everywhere.

 

Benefits of the CastleVax Platform

 

  • • NDV being a respiratory virus is ideally suited for mucosal delivery

    • Systemic delivery also highly effective

  • • In contrast to many other viral vectored vaccine approaches, there is no pre-existing immunity to NDV in the human population

  • • Up to 5kb of RNA can be inserted

  • • Allows foreign antigens to be incorporated into the viral particle

  • • Inactivated or Live attenuated

    • Monovalent, Bivalent, or Multivalent

  • • After enrolling over 10,000 subjects in our clinical studies, we find the vaccine platform to be safe and well tolerated

  • • Intranasal delivery results in induction of both systemic and mucosal immune responses

 

It All Starts With CVAX-01

Learn about our next-generation intranasal COVID-19 vaccine (CVAX-01), the promising results we’ve seen thus far, and the extraordinary potential of our pipeline.

Our Product Candidates

The performance of CVAX-01 reflects the strength of our platform:

  • Can target mucosal immunity (SARS-CoV-2 specific)

  • Induces a strong innate and exceptional adaptive immune response (SARS-CoV-2 specific)

  • Lower side effect profile when compared to existing mRNA vaccines (low reactogenicity)

  • Flexible and easy to engineer new strains and new viruses with potential for multivalent vaccination regimen

  • Allows for manufacturing at a lower cost